Compare Enveric Biosciences Inc (ENVB) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Remitly Global Inc — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Remitly Global Inc trades at $25.6 (market cap $5.26B). The key difference: Remitly Global Inc is far larger — about 988.7× Enveric Biosciences Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | RELY | |
|---|---|---|
Market Cap | $5.32M | $5.26B |
Sector | Health | Technology |
52-Week High | $17.40 | $24.96 |
52-Week Low | $1.28 | $12.20 |
Enterprise Value | $408.82K | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
RELY stock trades at $25.57, up 8.72% in the last 24 hours, showing strong momentum. The company demonstrates accelerating revenue growth from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. Technical indicators show bullish momentum with the current price near resistance at $26. Recent expansion into UAE and Canadian markets positions the company for continued international growth.
RELY presents a compelling growth story with improving profitability and strong analyst support (92% buy ratings). However, elevated valuation multiples (P/E 52) and competitive pressures in the remittance space warrant caution. The stock's upside potential to the $27.40 consensus target appears reasonable given accelerating revenue and expanding margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
